米拉珠单抗(Milatuzumab) - 药物靶点：CD74_在研适应症：系统性红斑狼疮_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Humanised anti-CD74、Milatuzumab (USAN)

+ [2]

靶点

CD74

作用机制

CD74抑制剂(HLA-DR抗原相关不变链抑制剂)

治疗领域

免疫系统疾病皮肤和肌肉骨骼疾病

在研适应症

系统性红斑狼疮

非在研适应症

急性移植物抗宿主病急性淋巴细胞白血病急性髓性白血病+ [10]

原研机构

Immunomedics, Inc.

在研机构

Immunomedics, Inc.

非在研机构

Gilead Sciences, Inc.

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评孤儿药 (美国)

序列信息

Sequence Code 13007608L

来源: *****

Sequence Code 9976219H

来源: *****

关联

8

项与米拉珠单抗相关的临床试验

NCT01663766 / Terminated临床1期

A Phase I Study of Milatuzumab (hLL1) for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients With Hematologic Malignancies

This study will assess the safety and tolerability of milatuzumab (IMMU-115) when added to a standard regimen to prevent Graft vs. Host Disease (GVHD) in patients with hematologic malignancies undergoing stem cell transplant.

开始日期2013-12-01

申办/合作机构

Gilead Sciences, Inc.

[+1]

NCT01585688 / Terminated临床1/2期

A Phase I/II Study of Immunotherapy With hLL1-DOX in Patients With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

The primary objectives are to evaluate the safety and tolerability of hLL1-DOX, and to determine the maximum tolerated dose (MTD) regimen (in terms of a dose and its associated dosing schedule). The secondary objectives are to obtain information on efficacy, pharmacodynamics, pharmacokinetics, and immunogenicity, and to determine the optimal dose for subsequent studies.

开始日期2012-08-01

申办/合作机构

Gilead Sciences, Inc.

NCT00989586 / Completed临床1/2期IIT

A Phase I/II Study of Veltuzumab (IMMU-106, hA20), a Humanized Anti-CD20 Monoclonal Antibody, Combined With Milatuzumab (IMMU-115, hLL1), a Humanized Anti-CD74 Monoclonal Antibody, in Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma

A phase I dose escalation study of veltuzumab and milatuzumab in relapsed and refractory B-cell NHL. The phase I study will be followed by a pilot phase II study.

开始日期2009-09-01

申办/合作机构

Gilead Sciences, Inc.

100 项与米拉珠单抗相关的临床结果

登录后查看更多信息

100 项与米拉珠单抗相关的转化医学

登录后查看更多信息

100 项与米拉珠单抗相关的专利（医药）

登录后查看更多信息

34

项与米拉珠单抗相关的文献（医药）

2022-12-01·European Journal of Medicinal Chemistry

The first ADC bearing the ferroptosis inducer RSL3 as a payload with conservation of the fragile electrophilic warhead

Article

作者: Conilh, Louise ; Boumendjel, Ahcène ; Falson, Pierre ; Dumontet, Charles ; Nguyen, Kim-Anh

The iron-dependent, non-apoptotic cell death, known as ferroptosis is an emerging strategy for the development of anticancer drugs. RSL3 was identified as an activator of ferroptosis through the inhibition of the glutathione peroxidase 4 (GPX4) which plays a crucial role in the cellular lipid oxidative stress. RSL3 is characterized by the presence of an electrophilic chloroacetyl moiety, namely warhead which covalently bonds to the catalytic and nucleophilic selenocysteine residue (Sec46) of GPX4. Like the major ferroptosis inducers, RSL3 suffers from lack of selectivity toward tumor cells. In this study, we report the first synthesis of an antibody-drug conjugate (ADC) containing RSL3 fragment and trastuzumab with the aim to deliver the agent selectively to tumors. The synthesis uses a judiciously chosen strategy to preserve the vital but fragile warhead. Full characterization of the ADC was accomplished, demonstrating the generation of a homogeneous DAR 8 conjugate. The robustness of the synthesis was successfully applied to another ADC associating the anti-CD74 mAb milatuzumab. The ADC induces ferroptotic cell death through reactive oxygen species accumulation and increases the activity of doxorubicin. The ADC associating trastuzumab and RSL3 may therefore offer potential applications in vectorized therapy alone or in combination with conventional chemotherapies.

2021-07-01·Annals of the Rheumatic Diseases1区 · 医学

Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE)

1区 · 医学

Letter

作者: Wegener, William A ; Wallace, Daniel J ; Goldenberg, David M ; Figueras, Florence

Milatuzumab (hLL1) is a humanised IgG1κ antibody that reacts with a cell surface epitope of human CD74, the human leukocyte antigen (HLA) class-II associated invariant chain present on antigen-presenting cells (APCs), including B cells and dendritic cells.1 Although initially studied for oncologic malignancies,2–5 dysregulation of APCs may also occur in non-malignant disorders, and several preclinical studies showed that milatuzumab modestly inhibited B cell proliferation, enhanced spontaneous migration, alterations of adhesion molecule expression and chemotaxis important for lymphocyte recruitment,6 and also reduced production of interferon-α in stimulated peripheral blood mononuclear cells isolated from healthy donors and patients with systemic lupus erythematosus (SLE) (unpublished results). Migration inhibitory factor (MIF) is a cytokine that activates a multicomponent receptor comprising the CD74 ligand-binding …

2018-07-01·British Journal of Haematology2区 · 医学

A phase I‐II clinical trial of the anti‐CD74 monoclonal antibody milatuzumab in frail patients with refractory chronic lymphocytic leukaemia: A patient based approach

2区 · 医学

Article

作者: Berrebi, Alain ; Haran, Michal ; Shevetz, Olga ; Valinsky, Liora ; Shvidel, Lev ; Amram, Orna ; Braester, Andrei ; Shtalrid, Mordechai ; Shachar, Idit ; Mordich, Orly ; Greenberg, Shulamit ; Herishanu, Yair ; Marom, Ayelet ; Ruchlemer, Rosa ; Harpaz, Nurith ; Mirkin, Vita ; Shtreiter, Marina ; Binsky‐Ehrenreich, Inbal

100 项与米拉珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08944	-	-	DB12943

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
系统性红斑狼疮	临床2期	-	Immunomedics, Inc.	-
难治性B细胞淋巴瘤	临床1期	美国	Gilead Sciences, Inc.	2009-09-01
难治性慢性淋巴细胞白血病	临床1期	以色列	Gilead Sciences, Inc.	2009-04-01
盘状红斑狼疮	临床1期	美国	Immunomedics, Inc.	2007-01-01
狼疮性肾炎	临床1期	美国	Immunomedics, Inc.	2007-01-01
中枢神经系统狼疮血管炎	临床1期	美国	Immunomedics, Inc.	2007-01-01
浆细胞瘤	临床1期	美国	Immunomedics, Inc.	2007-01-01
急性淋巴细胞白血病	临床前	美国	Gilead Sciences, Inc.	2013-12-01
慢性淋巴细胞白血病	临床前	以色列	Immunomedics, Inc.	-
多发性骨髓瘤	临床前	美国	Immunomedics, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00989586 (Pubmed \| Br J Haematol) 人工标引	临床1/2期	B细胞淋巴瘤	35	milatuzumab+veltuzumab	(艱積糧淵積糧繭積憲遞) = 簾製齋壓艱餘壓獵窪選繭窪襯廠膚觸範糧網選 (觸製蓋鹽醖簾鏇餘鬱膚 ) 更多	积极	2015-06-01
				Veltuzumab 200 mg/m(2) weekly + Milatuzumab 16 mg/kg weekly	-
NCT00421525 (Pubmed \| Br J Haematol)	临床1期	浆细胞骨髓瘤难治	25	Milatuzumab 1.5 mg/kg	鹽繭鏇顧艱淵遞獵積願(餘觸觸遞艱願糧齋窪顧) = moderately decreased with treatment (median decrease, 34%) 築繭鬱顧網齋鬱憲餘獵 (淵鹽範簾淵製膚廠製鬱 ) 更多	-	2013-11-01
				Milatuzumab 4.0 mg/kg